January 16, 2017
Cresco Pharma requests trading halt
Creso Pharma Limited, the company that Creso Pharma, the company focused on cannabis derived therapeutics, requests that its securities to be placed in a trading halt.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 16, 2017
FIT Biotech Oy’s converts convertible notes into shares
Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy and Bracknor Investment,…
January 16, 2017
Chi-Med kicks off two cancer drug studies in China
AIM and Nasdaq listed pharmaceutical company, Hutchison China MediTech Limited (Chi-Med) has initiated two Phase II studies in China for testing cancer treatments.
January 16, 2017
University of Michigan Pancreatic Cancer Center, Immunovia partner up in fighting pancreatic cancer
University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating…
January 16, 2017
Safe Orthopaedics to sell bone substitute for its Walnut cage for cervical surgeries in Europe
Safe Orthopaedics has started selling a bone substitute for its Walnut cage for cervical surgeries in Europe.
January 16, 2017
Horizon Discovery broadens gene editing capabilities through extension of key CRISPR license and grant-funded research
Horizon Discovery has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include…
January 12, 2017
Pixium Vision completes 10 implants in its Iris II study
Pixium Vision, a company developing and commercializing innovative bionic vision systems, has completed 10 implants in its Iris II study.
January 12, 2017
Walloon (Belgium) government funds ASIT Biotech’s food allergies treatment research
The Walloon (Belgium) government has decided to fund its ASIT Biotech to help develop new drug candidates to treat the main food allergies caused by peanuts, cow’s milk and egg whites.
January 12, 2017
MaxCyte’s in Demonstrates CRISPR-Cas9 X-linked CGD gene repair study
MaxCyte has been engaged in a study with National Institutes of Health’s (NIH) allergy and infection section to show certain CYBB gene behaviour in patients with X-linked chronic granulomatous disease (X-CGD).
January 12, 2017
Ablynx starts Phase IIb RESPIRE study of RSV infections treatment
Ablynx has dosed the first patient in the Phase IIb “RESPIRE” dose-ranging efficacy study of ALX-0171, its novel inhaled drug…